Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Valganciclovir products are in shortage in Canada (2 of 6 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Feb 28, 2027.
An antiviral medicine used to treat and prevent cytomegalovirus (CMV) infection.
Products affected
2 / 6
In shortage since
Nov 14, 2016
Est. full return
Feb 28, 2027
Reports on file
19
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
AURO-VALGANCICLOVIR
50MG · POWDER FOR SOLUTION · AURO PHARMA INC
DIN 02535483 · since Oct 3, 2025, est. end Feb 28, 2027 · Requirements related to complying with good manufacturing practices.
Active shortage
APO-VALGANCICLOVIR
450MG · TABLET · APOTEX INC
DIN 02393824 · since Nov 14, 2016, no end estimate · Disruption of the manufacture of the drug.
reversed
TEVA-VALGANCICLOVIR
450MG · TABLET · TEVA CANADA LIMITED
DIN 02413825
reversed
TEVA-VALGANCICLOVIR
450MG · TABLET · TEVA CANADA LIMITED
DIN 02413825
reversed
TEVA-VALGANCICLOVIR
450MG · TABLET · TEVA CANADA LIMITED
DIN 02413825
Resolved
TEVA-VALGANCICLOVIR
450MG · TABLET · TEVA CANADA LIMITED
DIN 02413825 · ended Mar 26, 2024 · Disruption of the manufacture of the drug.
Resolved
AURO-VALGANCICLOVIR
450MG · TABLET · AURO PHARMA INC
DIN 02435179 · ended Mar 15, 2024 · Demand increase for the drug.
Resolved
VALCYTE
450MG · TABLET · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02245777 · ended Jan 31, 2024 · Delay in shipping of the drug.
Resolved
VALCYTE
450MG · TABLET · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02245777 · ended Nov 2, 2023 · Disruption of the manufacture of the drug.
Resolved
VALCYTE
50MG · POWDER FOR SOLUTION · CHEPLAPHARM ARZNEIMITTEL GMBH
DIN 02306085 · ended Nov 2, 2023 · Disruption of the manufacture of the drug.
Resolved
TEVA-VALGANCICLOVIR
450MG · TABLET · TEVA CANADA LIMITED
DIN 02413825 · ended Oct 25, 2023 · Disruption of the manufacture of the drug.
Resolved
TEVA-VALGANCICLOVIR
450MG · TABLET · TEVA CANADA LIMITED
DIN 02413825 · ended Jun 20, 2023 · Disruption of the manufacture of the drug.
Showing 12 of 19 reports. All reports are on file with Health Canada.
What's happening
Valganciclovir is currently affected by 2 active shortage reports filed with Health Canada by AURO PHARMA INC, APOTEX INC.
The reported causes are: requirements related to complying with good manufacturing practices; disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Valganciclovir is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AB).
Recent changes
No changes recorded yet.
Common questions
What is Valganciclovir used for?
An antiviral medicine used to treat and prevent cytomegalovirus (CMV) infection.
When will Valganciclovir be back in stock in Canada?
The latest manufacturer estimate is Feb 28, 2027. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Valganciclovir in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.